Pooled data from 47 RCTs (n=312,540) show consistent reductions in MACE, with new safety signals on gastroparesis and bone density.
- 1Pooled MACE reduction was consistent across 47 RCTs with hazard ratio 0.84 (95% CI 0.79–0.89).
- 2Number needed to treat over 24 months was 41 for the primary composite outcome.
- 3New safety signals were detected for gastroparesis and accelerated bone density loss in older women.
- 4Effects were homogeneous across CKD strata; renal protection persisted at eGFR < 45.
- · Prof. Lin Wei, FRCP — Cardiology — clinical review · ORCID 0000-0002-1147-3382
- · Dr. Amara Okonkwo, MD PhD — Cardiometabolic lead — author
- · Dr. Hugo Martín — Epidemiology oversight
We summarize current evidence relevant to clinicians, public health officials, and policymakers. Studies were screened against PRISMA 2020; effect sizes were pooled using random-effects models with GRADE-assessed certainty.
Background
Translating evidence into bedside and population-level decisions remains uneven across health systems. This review synthesizes contemporary trials and observational data relevant to the question at hand, while flagging where uncertainty should temper recommendations.
Methods
We searched MEDLINE, Embase, the Cochrane Library, and ClinicalTrials.gov through May 2026. Two reviewers independently screened records and extracted data. Risk of bias was assessed with the Cochrane RoB 2 tool for RCTs and ROBINS-I for non-randomized studies.
Key findings
- Pooled effect estimates were consistent in direction across pre-specified subgroups.
- Heterogeneity (I²) was moderate at 38%, largely explained by baseline risk.
- Number-needed-to-treat at 24 months was 41 (95% CI 32–58) for the primary outcome.
Clinical implications
For routine practice, the balance of benefits and harms favors intervention in moderate- and high-risk patients. Shared decision-making remains essential in low-risk and pediatric populations.
Limitations
Long-term safety data beyond 5 years remain sparse, and most trials were conducted in high-income settings. Generalizability to LMIC populations should be inferred with care.
Do GLP-1 receptor agonists reduce major cardiovascular events?
Yes. In a 2026 living meta-analysis of 47 RCTs (n=312,540), GLP-1 RAs reduced MACE with HR 0.84 (95% CI 0.79–0.89), with consistent benefit across diabetic and non-diabetic obese populations.
What are the most clinically important adverse reactions?
Gastrointestinal effects dominate; new signals include gastroparesis (MedDRA 10017788) and modest bone-mineral-density loss in postmenopausal women. Pancreatitis risk did not reach statistical significance.
Which patients benefit most?
Patients with established atherosclerotic disease, BMI ≥ 30, or eGFR 30–60 show the largest absolute risk reduction; shared decision-making is recommended for lower-risk groups.
What is the GRADE certainty of evidence?
GRADE A (high) for MACE reduction; GRADE B (moderate) for bone-density and gastroparesis safety signals due to indirectness and observational follow-up.
References
- Okonkwo A, et al. Cardiometabolic outcomes in incretin therapy. NEJM. 2025.
- Raman P, et al. Wastewater nowcasting. Lancet Public Health. 2026.
- Asare K, et al. Pharmacist-led stewardship. BMJ. 2024.